Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease.
OBJECTIVE
To evaluate if type 2 diabetes mellitus increase gingival crevicular fluid (GCF) levels of prostaglandin E(2) (PGE(2)), interleukin-1beta (IL-1beta), tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor-2 (PAI-2).


METHODS
Seventeen type 2 diabetic patients with periodontal disease (DM), 17 otherwise healthy periodontally diseased patients (PD) and 17 systemically and periodontally healthy control subjects (H) were enrolled. Clinical periodontal measurements were recorded at six sites/tooth. GCF samples were analyzed by ELISA. Data were tested by statistical tests.


RESULTS
DM group revealed lower IL-1beta levels than PD group (p<0.01). PGE(2), t-PA and PAI-2 levels were similar in DM and PD groups (p>0.05). PGE(2), t-PA levels were higher in DM and PD groups than H group (p<0.05). PAI-2 level was higher in DM group than H group (p<0.05). GCF total amount of PGE(2) in DM group exhibited significant correlations with all clinical periodontal measurements (p<0.05).


CONCLUSIONS
Type 2 diabetes in this study seems not to increase GCF levels of the evaluated inflammatory mediators.
Kardeşler
Levent
L
Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey.
Buduneli
Nurcan
N
Biyikoğlu
Başak
B
Cetinkalp
Sevki
S
Kütükçüler
Necil
N
D000328:Adult; D000368:Aged; D002747:Chlorpropamide / Q000031:analogs & derivatives* / Q000032:analysis; D003773:Dental Plaque / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000201:enzymology / Q000503:physiopathology*; D015232:Dinoprostone / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005883:Gingival Crevicular Fluid / Q000502:physiology*; D006801:Humans; D053583:Interleukin-1beta / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010510:Periodontal Diseases / Q000453:epidemiology*; D012016:Reference Values; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D000096926:Benzenesulfonamides
D002747:Chlorpropamide; D015232:Dinoprostone; D053583:Interleukin-1beta; D010959:Tissue Plasminogen Activator; C111224:API 2; D000096926:Benzenesulfonamides